Carmell Therapeutics (CTCX) 10-K/A 16 May 23 2022 FY Annual report (amended) Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2023	Mar. 17, 2023
Document Information [Line Items]
Document Type	10-K/A
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-40228
Entity Registrant Name	Alpha Healthcare Acquisition Corp. III
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1645738
Entity Address, Address Line One	1177 Avenue of the Americas
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10036
City Area Code	646
Local Phone Number	494-3296
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Public Float		$ 148,572,270
Entity Central Index Key	0001842939
Amendment Flag	true
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Description	References throughout this Amendment No. 1 to the Annual Report on Form 10-K/A to “we,” “us,” the “Company” or “our company” are Alpha Healthcare Acquisition Corp. III unless the context otherwise indicates. This Amendment No. 1 to the Annual Report on Form 10-K/A (this “Amendment No. 1”) amends the Annual Report on Form 10-K of Alpha Healthcare Acquisition Corp. III (the “Company”) as of and for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (“SEC”) March 17, 2023 (the “Original 10-K Filing”). The Company has been informed by the SEC on May 15, 2023 of an error resulting from the omission of the introductory language in the Certifications 31.1 and 31.2 referring to internal control over financial reporting in paragraph 4 and paragraph 4(b) language referring to internal control over financial reporting included in the Original 10-K Filing. We are filing this Amendment No. 1 to amend and restate the Original 10-K Filing with modification as necessary to reflect the changes in the Certifications. The following items have been amended: Exhibit 31.1. Certification of Chief Executive Officer Pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. Exhibit 31.2. Certification of Chief Financial Officer Pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended.
ICFR Auditor Attestation Flag	false
Auditor Name	Adeptus Partners, LLC
Auditor Firm ID	3686
Auditor Location	New York, New York
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	ALPA
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding			15,907,985
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding			3,861,026
Redeemable warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
Trading Symbol	ALPAW
Security Exchange Name	NASDAQ
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant
Trading Symbol	ALPAU
Security Exchange Name	NASDAQ